Vemurafenib(CAS: 918504-65-1)

Vemurafenib is a selective BRAF inhibitor used primarily in the treatment of melanoma. Its chemical formula is C20H22N2O2, and it is a white to off-white solid at room temperature. It exhibits good solubility in dimethyl sulfoxide and has a molecular weight of 326.39 g/mol. Vemurafenib is known for its targeted therapy approach against BRAF V600E mutant tumors.

Vemurafenib is mainly used in oncology to treat advanced melanoma, particularly in patients with BRAF V600E mutations. It is also utilized in research for studying BRAF inhibition and its effects on cancer cell proliferation. Additionally, it may have potential applications in other therapeutic areas, though clinical use is primarily focused on dermatology and oncology.

Vemurafenib is generally considered safe when used as directed in medical settings. However, it may cause side effects such as skin rash, photosensitivity, and gastrointestinal issues. Proper handling, including the use of protective gloves and avoiding direct sunlight, is recommended to minimize risks. Safety standards are in place to ensure its appropriate use in targeted cancer therapies.

Vemurafenib should be stored in a cool, dry place away from light. It is recommended to keep it at a temperature between 2°C to 8°C. Storage in airtight containers is essential to maintain its stability and prevent contamination. Avoid exposure to moisture and ensure it is kept in a secure location to preserve its potency and effectiveness.